Clinical Experience of Patients With Hepatitis C Treated With Direct-Acting Antivirals After Heart Transplantation

Lu, Y.-M.; Yang, Wei-Ling; Chang, Chung-Yi; Ling, Sheng-Ming; Liu, Chia-Ying; Wei, Jeng; Yang, Hou-Sheng

doi:10.1016/j.transproceed.2020.10.035

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Successful cases of DAA treatment of HCV-infected heart transplant recipients with no impact on levels of immunosuppressive drugs, graft rejection, or graft dysfunction have been reported. [43][44][45] Multiple reports on DAA use in patients infected by HCV viremic heart allografts are also emerging.…”

Section: Hcv Treatment In Heart Transplantationmentioning

confidence: 99%

“…In a report from Taiwan, 12 HCV‐infected patients who received a heart transplant were successfully treated with sofosbuvir and either ledipasvir or daclatasvir 1–9 years after transplant without serious adverse events, including three with compensated cirrhosis 42 . Successful cases of DAA treatment of HCV‐infected heart transplant recipients with no impact on levels of immunosuppressive drugs, graft rejection, or graft dysfunction have been reported 43–45 . Multiple reports on DAA use in patients infected by HCV viremic heart allografts are also emerging.…”

Section: Hcv Treatment In Heart Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C and heart transplantation: An update

Nunez,

Kelkar

2023

Clinical Transplantation

View full text Add to dashboard Cite

There are limited data regarding heart transplantation in the setting of hepatitis C virus (HCV) infection in either recipients or donors, as the practice was infrequent, given concerns of worse post‐transplant outcomes. This changed dramatically after the development of highly effective HCV therapies, namely direct‐acting antivirals (DAAs). Additionally, nucleic acid testing currently in use establishes more precisely the risk of HCV transmission from donors. As a result, chronic HCV infection in itself is no longer a barrier for heart transplant candidates, and the use of HCV‐positive organs for HCV‐infected and non‐infected transplant candidates has increased dramatically. A review of the literature revealed that in the pre‐DAA era, HCV seropositive heart transplant patients had a higher mortality than their seronegative counterparts. However, short‐term data suggest that the differences in survival have been erased in the DAA era. Heart transplantation from HCV‐viremic donors to HCV‐uninfected recipients has become increasingly common as the number of deceased donors with HCV viremia has increased over the past years. Preliminary outcome reports are very encouraging, although further data are needed with regard to long‐term safety. New information continues to be incorporated to optimize protocols that guide this practice.

show abstract